Sign In
Buy TENX
$12.25
+0.250 (+2.08%)
At Close: Jun 22, 2026
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Tuesday, 12'th May 2026
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthene
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th May 2026
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
07:00am, Monday, 04'th May 2026
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
07:00am, Wednesday, 22'nd Apr 2026
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?
01:59am, Thursday, 02'nd Apr 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $10.78 and trad
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
02:37am, Wednesday, 25'th Mar 2026
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $10.43 and traded as h
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 10'th Mar 2026
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients
Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)
02:06am, Monday, 09'th Mar 2026
Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the t
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
07:00am, Tuesday, 03'rd Mar 2026
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutica
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
07:00am, Wednesday, 04'th Feb 2026
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical
Tenax Therapeutics: A Speculative Buy
01:51am, Friday, 09'th Jan 2026
Tenax Therapeutics is a speculative BUY, driven by the commercial potential of levosimendan for PH-HFpEF and a favorable risk/reward profile. Levosimendan's Phase III trial remains well powered, but t
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
01:19pm, Monday, 05'th Jan 2026
Tenax Therapeutics (TENX) initiated with a Buy rating and a $25 price target, implying 127% upside based on DCF analysis. TNX-103, targeting PH-HFpEF, shows a high probability of Phase 3 success with
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average – What’s Next?
03:40am, Thursday, 18'th Dec 2025
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $6.85
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
09:16am, Wednesday, 17'th Dec 2025
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2
Tenax Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 25'th Nov 2025
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using
